Accelerating the market launch of a medicine: post-development strategies for greater efficiency

In the complex world of the pharmaceutical industry, the success of a Phase III clinical trial is often seen as the finish line. However, for the teams responsible for overall strategy, this moment marks the beginning of an equally crucial post-development phase. Once scientific research has proven the efficacy and safety of a molecule, the real challenge is to transform this technical success into a product that is accessible to patients as quickly as possible. The challenge is threefold: to meet a public health need, to ensure a rapid return on investment, and to maintain a competitive position in the face of the constant emergence of new therapies.

 

 

Regulatory anticipation to break the linearity of the timetable

Rapid market access depends above all on the company’s ability to stop viewing the stages sequentially and instead bring them together. Historically, Marketing Authorisation Applications (MAA) were only submitted once the clinical files had been completely closed. Today, industry leaders favour a proactive approach, consulting agencies as soon as pivotal studies are designed. The use of early access mechanisms is a major lever in this regard. In Europe, the European Medicines Agency’s (EMA) PRIME programme provides enhanced support and early dialogue, often paving the way for Accelerated Assessment. At the same time, in the United States, the FDA offers statuses such as Fast Track or Breakthrough Therapy, which can radically transform the submission timetable. It is also essential to understand the key differences in the approval of innovative therapies in order to choose the most favourable territory for a priority launch.

To save time, the aim is to reduce approval times through this accelerated assessment. In very specific contexts of public health emergencies or major unmet medical needs, the EMA may also authorise a “rolling review”. This mechanism, although less common outside of health crises, allows experts to evaluate quality modules and non-clinical data well before the results of the final clinical study are available. By anticipating the review of data in this way, this method makes it possible to obtain a scientific opinion much more quickly after the completion of phase III.

 

 

Industrial synchronisation: CMC at the service of marketing

The success of a therapy depends not only on its medical validation, but also on the laboratory’s ability to produce on a large scale according to the strictest standards. The CMC (Chemistry, Manufacturing and Controls) component often represents the insidious bottleneck of post-development. Anticipating industrial challenges means that the development of manufacturing processes must progress in tandem with clinical phases. The validation of sites and production lines must be initiated well before final authorisation is obtained. For innovative medicines, this step is critical. Particular attention must be paid to compliance manufacturing requirements. Even the slightest change in the process after clinical trials may require the company to prove bioequivalence, which would delay market launch by several months.

This forward planning also extends to logistics and raw materials. By securing stocks and anticipating packaging and labelling specific to the various European Union member countries, the healthcare industries ensure that the first launch units can be shipped as soon as the European Commission gives its approval. This reverse planning must incorporate all GMP (Good Manufacturing Practices) compliance requirements so that no inspection by the ANSM or any other national authority can block the product’s launch at the last minute.

 

 

Operational cross-functionality to break down internal silos

Real acceleration cannot happen without seamless coordination between internal teams. Too often, the regulatory affairs, production, quality and market access departments work in isolation, only sharing information at the end of each stage. To increase efficiency, it is essential to establish a culture of collaboration from the middle of the clinical development process onwards. Early integration of the constraints of each profession makes it possible to identify risks before they become insurmountable obstacles. For example, involving pharmacovigilance experts from the outset of the marketing authorisation application process makes it possible to structure a robust risk management plan that will meet the expectations of the authorities without requiring multiple back-and-forth exchanges.

This cross-functional approach also makes it easier to anticipate post-marketing pharmacovigilance obligations. By forming a multidisciplinary launch team, the company ensures that its commercial strategy is consistent with scientific promises and regulatory realities. This synergy is all the more valuable when it comes to choosing the right partners.

 

 

Anticipating availability through the new early access framework

In France, the early access system represents an exceptional opportunity for innovative medicines. This system, which followed the major reform of ATUs (Temporary Use Authorisations) in France, makes it possible to make a treatment available to patients who have reached a therapeutic impasse. This can be done even before the marketing authorisation has been officially granted. Beyond the ethical aspect and the immediate benefit to public health, early access is a key strategic tool. It allows financial coverage by health insurance to begin much earlier and enables the collection of extremely valuable real-world data. This data will then support the assessment by the Transparency Commission of the Haute Autorité de Santé (HAS) during negotiations on price and reimbursement rates.

Mastering the mechanics of early access requires meticulous preparation. It is necessary to demonstrate that the drug offers real therapeutic progress and that its implementation is safe. This system bridges the gap between the end of research and full commercialisation, enabling a smooth transition to the common market.

 

 

Preparing the commercial ground and perception of value

While obtaining marketing authorisation is a unified European step, effective patient access to treatment depends on decision-making processes specific to each Member State. Pricing and reimbursement decisions remain a national competence, requiring specific applications to be submitted to each local health authority as soon as marketing authorisation is granted.

This crucial step must be prepared well in advance of the EMA’s opinion so as not to delay the availability of the treatment. This involves building a solid case demonstrating the therapeutic and medico-economic value of the product according to the specific requirements of each country. In France, for example, the dossier must demonstrate the medical benefit and the improvement in medical benefit in order to justify the cost of the treatment to the Ministry of Health and Social Security. Only a detailed understanding of how a drug is marketed allows the strategy to be adapted to the specific regulatory and economic characteristics of each territory.

 

 

Accelerating the arrival of a drug on the market is a high-precision exercise. There is no room for improvisation when managing key stages, making it strategically essential to rely on an expert partner. Alhena Consult supports you in transforming these challenges into opportunities for growth. Thanks to our operational support and expertise in regulatory affairs, we ensure that your strategy is consistent so that your innovations achieve their ultimate goal: treating patients effectively and quickly.